Tuesday, April 19, 2016

Plasma circulating cell-free mitochondrial DNA in the assessment of Friedreich's ataxia

Subrahamanyam Dantham, Achal K. Srivastava, Sheffali Gulati, Moganty R. Rajeswari, Journal of the Neurological Sciences, Available online 14 April 2016, ISSN 0022-510X, doi:10.1016/j.jns.2016.04.016.

Despite several therapies under study or in development for FRDA, evaluation of therapeutic efficacy is limited by the lack of minimally invasive biomarkers to assess disease progression and severity.
Our study identified three major findings, 1. FRDA patients showed decrease in the levels of plasma mtDNA, whereas plasma nDNA was increased. 2. Plasma mtDNA has shown to exhibit high sensitivity and specificity in discriminating FRDA patients from the healthy controls over plasma nDNA levels 3. Significant serial changes have been observed in case of plasma mtDNA upon intervention with nutrient supplement (omega-3 fatty acids).
In view of their neuro-cardio protective role and positive effect on mitochondrial metabolism in ameliorating the neuro symptoms, the Omega-3 fatty acids (Eicosapentaenoic acid and docosahexaenoic acid) have been recommended as a nutritional supplement


 Plasma circulating cell-free mitochondrial DNA in the assessment of Friedreich's ataxia